BMXP Holdings

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases. The company utilizes its proprietary BOLT platform to rapidly identify, characterize, and synthesize phage combinations that address specific bacterial strains associated with conditions such as cystic fibrosis and atopic dermatitis. BiomX's lead program, BX004, is currently being evaluated in Phase 2 clinical trials for the treatment of chronic lung infections in cystic fibrosis patients caused by Pseudomonas aeruginosa. Additionally, the company is advancing BX005 for atopic dermatitis and exploring phage-based applications in oncology, specifically targeting Fusobacterium nucleatum in colorectal cancer. By leveraging the precision of bacteriophages, BiomX aims to provide highly specific antimicrobial solutions that avoid the broad-spectrum disruption of the healthy microbiome.